Navigation Links
Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009
Date:11/11/2009

Bavarian Nordic expects that an end of phase II meeting with the FDA will take place during January 2010. While partnership negotiations are ongoing, the company is in preparations for Phase III and these are proceeding as planned.

Lately, the prostate cancer field has witnessed positive clinical results followed by attractive partnership deals. It has proven worthwhile for a number of companies to independently advance their projects into Phase III, thus maximising their value before they would eventually sign a licensing deal. Similarly, Bavarian Nordic is seeking to maximise and retain the value of its cancer portfolio. Consequently, Bavarian Nordic seeks the ability to advance PROSTVAC(TM) into Phase III of its own. In order for Bavarian Nordic to gain the independence to execute its short and long term activities within biodefence and cancer, the company is exploring available options for securing an optimum financial position.

Highlights from the period

Bavarian Nordic has signed contract with an EU country for the delivery of IMVAMUNE(R)

In September, Bavarian Nordic signed a contract with the military of an undisclosed EU country for the delivery of a small order for IMVAMUNE(R). The size and value of the contract is undisclosed. This marks the first time, Bavarian Nordic enters a contract with an EU country for the delivery of IMVAMUNE(R), and it demonstrates that there exists a real demand inside of EU for new and safer smallpox vaccines for preparedness stockpiles. The vaccines have been delivered.

Negotiations with the US authorities for the further development of IMVAMUNE(R)

Bavarian Nordic is currently in late-stage negotiations with the US authorities for a new contract to develop a freeze-dried version of the IMVAMUNE(R) smallpox vaccine. This potential new project will have no influence on the ongoing RFP-3 contract for the procurement of 20 million doses of IMVAMUNE(R) and the
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Bavarian Nordic Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R)
2. Bavarian Nordic A/S - Half Year Interim Report 2009
3. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
4. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
5. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
6. Bavarian Nordic Publishes its Annual Results 2008
7. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
8. Bavarian Nordics Case Against Oxford BioMedica
9. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
10. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
11. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) announced today that ... an update on the progress of Sangamo,s ZFP Therapeutic ® ... strategy at 1:30pm ET on Monday, June 1, 2015, at ... held in New York, NY . ... accessed via a link on the Sangamo BioSciences website in ...
(Date:5/26/2015)... -- Alere Inc. (NYSE: ALR ) (the "Company") announced today ... its Quarterly Report on Form 10-Q for the three months ... a notice from the New York Stock Exchange (the "NYSE") ... continued listing requirements under the timely filing criteria established in ... The reason for the delay relates to Company,s need ...
(Date:5/26/2015)... Global Stem Cells Group and Stem ... first cellular and regenerative medicine symposium in Barcelona Spain ... stem cell training class Oct. 10. The event will ... of Therapeutic Confrontations (CONFTERA) in Barcelona. , In ... medicine and recent advances in cellular therapies, Global Stem ...
(Date:5/26/2015)... May 26, 2015   PDI , a ... announced that Oakwood Healthcare in Dearborn, ... winning entry in Delivering the Difference ... display excellence in building collaborative relationships between infection ... healthcare facilities.  Oakwood Healthcare,s infection ...
Breaking Biology Technology:Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3
... May 3, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: ... a leading China-based biotechnology company focused on researching, ... that it will release its first quarter 2011 ...  closes on Wednesday, May 11, 2011 at 8:00pm ...
... this year,s American Academy of AntiAging (A4M) conference, Glycation and ... in premature aging and disease. AGEs are dangerous substances that ... attaches to a protein or lipid without the presence of ... cause accelerated damage to the tissues and cells. ...
... Pharmaceuticals, Inc. (AMEX: AEN ), a developer ... announced today that after scientific review, the ongoing clinical ... multiple sclerosis (MS) has received an additional $1,594,553 in ... of Neurological Disorders and Stroke (NIH/NINDS). The clinical trial ...
Cached Biology Technology:3SBio Inc. Schedules Unaudited First Quarter 2011 Results 2At This Year's American Academy of AntiAging (A4M) Conference, Glycation and AGEs (Advanced Glycation End Products) Were Named the Leading Factors in Premature Aging and Disease 2Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 2Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 3Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 4
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2
... Access to Research Careers) Program has announced the travel ... of Chicanos and Native Americans in Science (SACNAS) annual ... These awards are meant to promote the entry of ... mainstream of the basic science community and to encourage ...
... Fox Foundation for Parkinson,s Research and Shake It Up ... Sydney,s Garvan Institute of Medical Research to look at ... Long non-coding RNAs are complex molecules, produced from ... in the body. Unlike conventional genes, they do not ...
... have increasingly relied on the wild and weedy relatives of ... and other traits. But just like all wild plant species, ... decline and extinction due to habitat loss, pollution, and climate ... describe the latest efforts to identify and protect the wild ...
Cached Biology News:Garvan Institute receives grant to research role of long non-coding RNAs in Parkinson's disease 2Protecting the weedy and wild kin of globally important crops 2
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
For demonstration of Helicobacter pylori...
... with SR-101 Labeled Substrates (red fluorescence; ... measure serine protease activation • No ... FLISP Kits utilize cell-permeable, fluorescently labeled ... measure chymotrypsin-like activity in whole living ...
... the mitochondrial transmembrane potential is ... events that occur following induction ... Detection Kit utilizes a lipophilic ... a mitochondrial activity marker. MitoLight ...
Biology Products: